Zimmer Biomet Q1 EPS Forecast Reduced by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities research analysts at Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for Zimmer Biomet in a research note issued to investors on Monday, March 10th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $1.77 per share for the quarter, down from their previous forecast of $1.80. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q2 2025 earnings at $2.03 EPS, FY2025 earnings at $8.23 EPS, Q2 2026 earnings at $2.23 EPS, Q3 2026 earnings at $2.15 EPS, Q4 2026 earnings at $2.30 EPS, FY2026 earnings at $8.79 EPS and FY2027 earnings at $9.28 EPS.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the business posted $2.20 earnings per share.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Truist Financial reiterated a “hold” rating and set a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Royal Bank of Canada lowered their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Barclays lowered their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Finally, Raymond James lowered their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $107.36 on Tuesday. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock’s fifty day simple moving average is $105.68 and its two-hundred day simple moving average is $107.08. Zimmer Biomet has a 1-year low of $97.69 and a 1-year high of $133.90. The stock has a market cap of $21.37 billion, a PE ratio of 24.13, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.

Institutional Trading of Zimmer Biomet

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Stonebridge Financial Group LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $25,000. Dunhill Financial LLC raised its holdings in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet during the third quarter valued at approximately $28,000. Menard Financial Group LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $30,000. Finally, Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the third quarter valued at approximately $35,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.95% of the stock is owned by company insiders.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.